Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.
about
Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situImmunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.Pathogenesis of human immunodeficiency virus infectionHuman immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41Role of the DIS hairpin in replication of human immunodeficiency virus type 1Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles.Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis.The good and evil of complement activation in HIV-1 infectionCharacterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase geneStoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1.Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.Distinct mechanisms of CD4+ and CD8+ T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions.Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.Functional chimeras of human immunodeficiency virus type 1 Gp120 and influenza A virus (H3) hemagglutininT cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans.A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replicationModifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1.Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.Biologic studies of chimeras of highly and moderately virulent molecular clones of simian immunodeficiency virus SIVsmPBj suggest a critical role for envelope in acute AIDS virus pathogenesis.Infectious entry by amphotropic as well as ecotropic murine leukemia viruses occurs through an endocytic pathwayBiochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical TriaEnhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virusA mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41.MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1.Virus receptors: implications for pathogenesis and the design of antiviral agents.Cleavage of a Neuroinvasive Human Respiratory Virus Spike Glycoprotein by Proprotein Convertases Modulates Neurovirulence and Virus Spread within the Central Nervous SystemDefining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivityNascent human immunodeficiency virus type 1 reverse transcription occurs within an enveloped particleInsertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchProducer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein.Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody
P2860
Q21090535-F021BE8E-1FDD-4DFE-8E68-05238EA7A6E8Q24531479-FA116156-26FE-46A4-B71C-3EE4C0D7F307Q24634681-A6D925A8-0713-4CA4-B2E0-06A2A30E882CQ24675546-A3DA9588-D54C-473B-8249-58076D2751A6Q24680551-1A9802D5-7F1A-4610-A960-45C7E4B3921CQ24791794-824EFC35-2554-47FC-BA15-2A44736920F5Q24802514-B2C77452-B170-41AA-93C7-F8959A878639Q27635422-6A868EE1-FD22-4C94-BC9B-F593EC7DB1FAQ28275986-0EE86439-D822-4284-9582-CF175A48C0E4Q28646835-5677348A-B22D-4A87-AD63-BEA2F618BE76Q29615351-2196C06A-431D-435F-A02D-4B5F2EC53C15Q30447936-1B550E49-6A43-4347-B682-AF3C53565856Q30480956-DB3000B1-0E68-47E8-8537-D124F3FC79A5Q33724169-645AC588-6511-4973-99F3-E8ADEBF226FCQ33780497-09E5F79F-FD01-46A7-ABAA-0C088EC13ED0Q33780524-48FF3DD6-DA55-437D-9149-E1E950D6E49BQ33780529-1F8BB628-64B7-4053-B96A-422E847096FCQ33782387-B658FBF0-3249-4F93-82CF-8C5B5A64889FQ33782608-B7320010-E183-49F4-8E26-ACCBDB53E905Q33790492-FEC04C91-03B5-4C20-8854-00F9736D9692Q33804811-FB30F9E9-1537-4470-BAF1-23FC130529E2Q33806056-BD1211CF-07FB-4385-8D32-85EA888C8DC9Q33806303-7EBBC8F2-39EE-4A3C-9073-C8C01710C456Q33836042-E51054B9-1FCF-4B56-AA78-28A423229147Q33843723-D686E4DE-450A-4150-9E9B-4501C7848152Q33851643-2D3DE41D-D325-4DEB-8353-0E72538578F3Q33930424-E272F0D4-CD6C-42BE-896B-C8ADE65BCB45Q34171212-A277815A-E8D9-4E0A-A9BD-468AF1989CEBQ34332728-FEDC3E9C-6456-4897-B1C4-57572EFD3995Q34364045-065717A2-6855-47E4-AEB8-25465A0B92E4Q34434813-4387F504-5FFE-4683-B664-545C80BD9DABQ34681455-AA80B4EA-1B7C-41A8-942B-DE62DE1907FDQ35366667-7CE624FA-64D0-4EB0-A4E2-5783C1A7BB01Q35834560-77AA5E53-57E5-4504-9C57-250B08CFC983Q35838533-137DB1EA-7898-4CBF-9E17-7E5D3638A73BQ35839880-D93EC2F7-FEB0-45DA-8961-780605A54B91Q35848446-85B07411-2B29-4B47-B462-B6E511E4EB7FQ35861256-EF4613BB-0DC7-494C-8991-6B8042D8EFBEQ35863401-AC44C520-4BF1-4E9D-9F1D-72FE848737D8Q35866030-FB887164-BA0E-460F-80EE-F927FAA3595D
P2860
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Differential loss of envelope ...... nfectivity and neutralization.
@en
type
label
Differential loss of envelope ...... nfectivity and neutralization.
@en
prefLabel
Differential loss of envelope ...... nfectivity and neutralization.
@en
P2093
P2860
P1433
P1476
Differential loss of envelope ...... nfectivity and neutralization.
@en
P2093
McKeating JA
McKnight A
P2860
P304
P407
P577
1991-02-01T00:00:00Z